iPSC Differentiation to Haemogenic Progenitor Cells Without Purification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current adoptive T cell therapies are limited by a lack of suitable patient and tumor-specific T cells, necessitating the development of methods to produce therapeutically sufficient and functional antigen-specific T cells for effective immunotherapy.
Innovation Solution
Haemogenic progenitor cells, such as haemogenic endothelial cells (HECs) and haematopoietic progenitor cells (HPCs), are produced from induced pluripotent stem cells (iPSCs) without intermediate purification or isolation steps, allowing for the generation of T cells in a single culture vessel without serum or stromal co-culture, and can differentiate into T cells, NK cells, or B cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If intermediate purification or isolation steps are used in the differentiation process, then cell purity may be improved, but process complexity and time are increased
Solution Approach 1:
The invention extracts and removes the intermediate purification or isolation steps from the traditional differentiation process. By eliminating these intermediate steps, the method achieves a simplified continuous differentiation process from iPSCs to HPCs without compromising cell quality, directly resolving the contradiction between purity and process complexity
Solution Approach 2:
The differentiation process is segmented into defined sequential stages (mesoderm formation, HEC differentiation, HPC generation) that can proceed continuously without intermediate purification. Each stage is optimized to maintain cell quality while avoiding the need for complex isolation steps
2Reliability
If serum or stromal co-culture is used in the differentiation process, then cell support and guidance may be improved, but process complexity and contamination risk are increased
Solution Approach 1:
The invention enables the differentiation system to be self-sufficient by replacing serum and stromal co-culture with defined culture conditions. The process uses chemically defined media and controlled differentiation factors that guide cell fate without requiring external stromal support, achieving both reliability and simplicity
Solution Approach 2:
The invention changes the cultural parameters from undefined serum-based conditions to defined chemically controlled conditions. By adjusting differentiation factors, growth factors, and media composition in a controlled manner, the process achieves reliable cell differentiation without the complexity of stromal co-culture systems
3Manufacturing precision
If multiple purification steps are implemented, then cell quality may be improved, but production time and cost are increased
Solution Approach 1:
The invention extracts multiple purification steps from the traditional workflow and replaces them with a continuous differentiation approach. By maintaining cells in defined culture conditions throughout the differentiation process, the method achieves high cell quality without the time loss associated with repeated purification cycles
Solution Approach 2:
The invention performs preliminary optimization of culture conditions and differentiation protocols to ensure high cell quality is achieved during the continuous differentiation process itself. This preliminary optimization eliminates the need for subsequent purification steps, thereby reducing production time while maintaining cell quality
Data Source
AI summary
This invention relates to the production of a population of haemogenic progenitor cells by (i) differentiating a population of induced pluri potent stem cells (IPSCs) into mesoderm cells and; (II) differentiating the mesoderm cells to produce a population of haemogenic progenitor cells. Steps (i) and (ii) are performed without purification or isolation of cells in the population. In addition, the haemogenic progenitor cells may be produced without the use of serum or stromal co-culture. Methods of the invention may be useful for example, in the production of clinical grade blood cells, such as T cells, for use in immunotherapy.